News
ALBO
--
0.00%
--
Wedbush Maintains Outperform on Albireo Pharma, Raises Price Target to $84
Wedbush analyst Liana Moussatos maintains Albireo Pharma (NASDAQ:ALBO) with a Outperform and raises the price target from $82 to $84.
Benzinga · 2d ago
Wedbush Adjusts Albireo Pharma PT to $84 From $82, Maintains Outperform Rating
MT Newswires · 2d ago
Wedbush Adjusts Albireo Pharma's PT to $84 from $82 After EU Launch of Bylvay Begins in Germany, Keeps Outperform Rating
MT Newswires · 2d ago
Albireo Announces Bylvay (odevixibat) Now Available In Germany
Albireo Pharma, Inc. (NASDAQ:ALBO), a rare pediatric liver disease company developing novel bile acid modulators, today announced that Bylvay (odevixibat), the first drug approved in Europe for the treatment of all types
Benzinga · 3d ago
BRIEF-Albireo Reports Bylvay Now Available In Germany
reuters.com · 3d ago
Albireo Announces Bylvay(R) (odevixibat) Now Available in Germany
- Listed on the German national price list and all pharmacy software programs -
GlobeNewswire · 3d ago
Albireo Pharma Launches Bylvay in Germany
MT Newswires · 3d ago
Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Albireo Pharma, Inc. (Nasdaq: ALBO), a rare pediatric liver disease company developing novel bile acid modulators, today announced the grant of inducement stock options exercisable for an aggregate of 15,000 shares of Albireo's common stock and restricted ...
GlobeNewswire · 09/08 20:30
BRIEF-Albireo Receives UK MHRA Approval Of Bylvay (Odevixibat)
reuters.com · 09/08 12:58
Albireo Receives UK MHRA Approval of Bylvay® (odevixibat)
– Bylvay now approved in U.S., EU and UK as first drug treatment for patients with PFIC – – Only once-daily drug indicated to treat all forms of PFIC – – MHRA decision based on data from the largest Phase 3 PFIC trial to date – BOSTON, Sept. 08, 2021 (GLOB...
GlobeNewswire · 09/08 12:30
Albireo Pharma Wins UK Ok of Bylvay for Progressive Familial Intrahepatic Cholestasis
MT Newswires · 09/08 10:26
Albireo Pharma Sells Bylvay-Associated PRV For $105M
Benzinga · 09/07 15:04
BRIEF-Albireo Sells Priority Review Voucher For $105 Mln
reuters.com · 09/07 13:51
Albireo Sells Priority Review Voucher For $105M
– PRV was granted to Albireo with the FDA approval of BylvayTM (odevixibat) in July – – Non-dilutive capital further strengthens the Company's financial position – BOSTON, Sept. 07,
Benzinga · 09/07 12:37
Albireo Sells Priority Review Voucher (PRV) for $105 Million
- PRV was granted to Albireo with the FDA approval of Bylvay (odevixibat) in July -
GlobeNewswire · 09/07 12:30
Albireo Pharma To Sell Priority Review Voucher For $105 Million
MT Newswires · 09/07 10:00
Albireo to Present at Upcoming Investor Conferences
BOSTON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, Simon Harford, Chief Finan...
GlobeNewswire · 09/02 12:30
Looking into Albireo Pharma's Return on Capital Employed
After pulling data from Benzinga Pro it seems like during Q2, Albireo Pharma (NASDAQ:ALBO) posted sales of $2.43 million. Earnings were up 16.96%, but Albireo Pharma still reported an overall loss of $33.03 million.
Benzinga · 08/27 21:12
Albireo Pharma Enters Deal With Genpharm to Commercialize Liver Disease Drug in Saudi Arabia, Gulf Region
MT Newswires · 08/18 06:23
BRIEF-Albireo And Genpharm Announce Agreement To Commercialize Bylvay (Odevixibat) In Saudi Arabia And Gulf Region
reuters.com · 08/18 05:33
Webull provides a variety of real-time ALBO stock news. You can receive the latest news about Albireo Pharma through multiple platforms. This information may help you make smarter investment decisions.
About ALBO
Albireo Pharma, Inc., formerly Biodel Inc., is a specialty biopharmaceutical company. It is focused on the development and commercialization of bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI), disorders where improper flow or absorption of bile causes serious medical conditions for which there is unmet need. The target indication for its lead product candidate, A4250, is progressive familial intrahepatic cholestasis (PFIC), which is a genetic disorder affecting children. A4250 is being evaluated in a Phase II clinical trial. Other products in the Company's pipeline include Elobixibat, A3384 and Bile Acid Modulators. Elobixibat is indicated for the treatment of chronic constipation and it has completed its Phase III clinical trials. A3384 is a formulation of cholestyramine that is designed to release cholestyramine directly in the colon. It has completed a Phase II clinical trial of a prior formulation of A3384 in bile acid malabsorption (BAM).